A Phase 2 interventional study of Perampanel Oral Suspension and Perampanel Tablet in Pediatric Epileptic Syndrome and Partial-onset Seizures, sponsored by Eisai Inc.. Active, not recruiting at 35 sites in 6 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing perampanel in Epilepsy — none open to participants now, 1 under way, none of them phase 3. perampanel · Epilepsy.
Among the 28 studies testing perampanel in Epilepsy, this one is the 8th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2019, is one of 10 in phase 2, and was the 19th registered.
1,850 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 28 studies testing perampanel in Epilepsy is open now. The open studies under Epilepsy, anywhere →
perampanel: first FDA approval 2012 (FYCOMPA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 112 (39%) set no upper age limit and 149 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 100 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 26 across the 27 interventional studies. Of the 25 that completed or were terminated, 16 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
51 studies in Epilepsy by Eisai Co., Ltd.: none open now, 1 under way, none of them phase 3. Of 48 finished, 30 (63%) have results posted.
Among the 51 studies in Epilepsy by Eisai Co., Ltd., this one is the 21st largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 in phase 2, and was the 47th registered.
Eisai Co., Ltd.’s Epilepsy studies by the year they started, since 2002.
1 of the studies testing perampanel in Epilepsy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04015141Eisai Inc.A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy | 2027-04-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing perampanel in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 51 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
This study will consist of a Core Study, Extension Phase A and Extension Phase B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants aged 1 month to less than 18 years with pediatric epileptic syndrome (Cohort 1) or aged 1 month to less than 2 years with POS (Cohort 2) will receive perampanel oral suspension or perampanel tablets, once daily up to 56 weeks.
Drug: Perampanel Oral Suspension · Drug: Perampanel Tablet
Perampanel oral suspension.
Also known as: E2007, Fycompa
Perampanel tablet.
Also known as: E2007, Fycompa
Proportion of 50% Responders For All Seizures During the Maintenance Period of Core Study
A response of 50% will be defined as a decrease in 28-day seizure frequency of equal or greater than 50% compared to baseline seizure frequency.
Time frame: Week 10 to Week 23
Proportion of 50% Responders During Treatment Period of Core Study and Extension Phase A
A response of 50% is defined as a decrease in 28-day seizure frequency of equal or greater than 50% compared to baseline seizure frequency.
Time frame: Treatment Period of Core Study and Extension Phase A: Week 0 to Week 56
Proportion of 25% and 75% Responders for all Seizures, During Maintenance Period of Core Study and During Treatment Period of Core Study and Extension Phase A
A response of 25% is defined as a decrease in 28-day seizure frequency of equal or greater than 25% compared to baseline seizure frequency. 75% response is defined as a decrease in 28-day seizure frequency of equal or greater than 75% compared to baseline seizure frequency.
Time frame: Maintenance Period of Core study: Week 10 to Week 23; Treatment Period of Core Study and Extension Phase A: Week 0 to Week 56
Proportion of Participants Who Are Seizure-Free During the Maintenance Period of Core Study and During the Treatment Period of Core Study and Extension Phase A
Time frame: Maintenance Period of Core study: Week 10 to Week 23; Treatment Period of Core Study and Extension Phase A: Week 0 to Week 56
Change From Baseline in Seizure Frequency For All Seizures During the Treatment Period of Core Study and During the Treatment Period of Core Study and Extension Phase A
Time frame: Baseline, Treatment Period of Core study: Week 23, Treatment Period of Core Study and Extension Phase A: Week 56
Percent Change From Baseline in Seizure Frequency For All Seizures During the Treatment Period of Core Study and During the Treatment Period of Core Study and Extension Phase A
Time frame: Baseline, Treatment Period of Core study: Week 23, Treatment Period of Core Study and Extension Phase A: Week 56
Clinical Global Impression of Change (CGIC) at the End of the Treatment Period of Core Study and at the End of Extension Phase A
Assessment of disease severity will utilize the CGIC scale at end of treatment to evaluate participant's change in disease status since initiation of treatment. The CGIC is a 7-point scale that measures a physician's global impression of a participant's clinical condition. Scale ranges from 1 to 7 with lower scores indicating improvement (1=very much improved, 2=much improved, 3=minimally improved), higher scores indicating worsening (5=minimally worse, 6= much worse, 7=very much worse), and a score of 4 indicating no change.
Time frame: Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Subject Global Impression of Change (SGIC) at the End of the Treatment Period of Core Study and at the End of Extension Phase A
SGIC is a 7-Point scale that provides a participant-determined summary measure of change from baseline of participant's status. Scale ranges from 1 to 7 with lower scores indicating improvement (1=very much improved, 2=much improved, 3=minimally improved), higher scores indicating worsening (5=minimally worse, 6= much worse, 7=very much worse), and a score of 4 indicating no change.
Time frame: Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Change From Baseline in the Cognitive Drug Research (CDR) Parameter at the End of the Treatment Period of Core Study and at the End of Extension Phase A
The CDR System Global Cognition Score (cognitive test battery) is derived from 5 CDR System domain scores, also called factor scores: Power of Attention, Continuity of Attention, Quality of Episodic Memory, Quality of Working Memory, and Speed of Memory. The CDR assessment and Child Behavior Checklist (CBCL) will be administered to participants 6 years and over and 2 years and over, respectively, using an age-appropriate version to assess cognitive function and behavior.
Time frame: Baseline, Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Change from Baseline in CBCL Parameters at the End of the Treatment Period of Core Study and at the End of Extension Phase A
The CBCL is a questionnaire to assess behavioral and emotional problems in children as reported by the primary caregiver. It is standardized to evaluate maladaptive behavioral and emotional problems in ages 1.5 to 5 years (CBCL 1.5/5) or 6 to 18 years (CBCL). The CBCL examines three domains (Social Functioning, Mood and Anxiety Symptoms, and Externalizing Symptoms) by assessing 140 problem items that describe specific behavioral and emotional problems. Respondents indicate how accurately the statements describe the child by selecting from options on a 3-point Likert-type scale (0=Not True, 1= Somewhat or Sometimes True, or 2=Very True or Often True).
Time frame: Baseline, Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Change from Baseline in Lafayette Grooved Pegboard Test (LGPT) Parameters at the End of the Treatment Period of Core Study and at the End of Extension Phase A
LGPT measures visuomotor skills. This test is a manipulative dexterity test that consist of a metal matrix of 25 holes with randomly positioned slots. Participants require to insert 10 grooved pegs into the holes. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. The task is timed and the scores are the time taken for the participant to complete all 10 pegs for each hand. If the test cannot be completed within 300 seconds, 300 seconds are recorded for the time. An increase in score (longer time) indicates worsening of visuomotor skills.
Time frame: Baseline, Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Change from Baseline in Growth and Development Parameter - Height
Time frame: Baseline, Treatment Period of Core Study: Week 23; Extension Phase A: Weeks 28, 40, and 56
Change from Baseline in Growth and Development Parameter - Weight
Time frame: Baseline, Treatment Period of Core Study: Weeks 2, 5, 8, 10, 14, 18 and 23; Extension Phase A: Weeks 28, 40, 56, and 60
Change from Baseline in Growth and Development Parameter - Free Triiodothyronine (fT3) and Free Thyroxine (fT4) Levels in Blood
Time frame: Baseline, Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Change from Baseline in Growth and Development Parameter - Thyroid-Stimulating Hormone (TSH) Levels in Blood
Time frame: Baseline, Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Change from Baseline in Growth and Development Parameter - Insulin Like Growth Factors (IGF)-1
Time frame: Baseline, Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Change from Baseline in Growth and Development Parameter- Sexual Maturation Assessed by Tanner Staging
Sexual maturation including pubic hair growth (both sexes), genital (males only) and breast (females only) development of participants will be assessed using Tanner Staging.
Time frame: Baseline, Treatment Period of Core Study: Week 23, Extension Phase A: Week 56
Proportion of Participants with any Treatment-Emergent Reports of Suicidal Ideation and Behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS) and Intensity of These Behaviors Assessed using C-SSRS Scores
C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS is used to assess whether participant experienced SI (1:wish to be dead; 2:non-specific active suicidal thoughts; 3:active SI with any methods (not plan) without intent to act; 4:active SI with some intent to act, without specific plan; 5:active SI with specific plan and intent) and suicidal behavior (6:actual attempt; 7:interrupted attempt; 8:aborted attempt; 9:preparatory acts or behavior; 10:suicidal behavior). An assessment of SI and behavior using the C-SSRS will be performed throughout the study for participants aged 6 years and above at the time of consent. In participants younger than 6 years, SI and behavior will be monitored based upon clinical impression.
Time frame: Treatment period of Core Study: Weeks 0, 2, 5, 8, 10, 14, 18, and 23; Extension Phase A: Weeks 28, 46, 56 and 60
Change from Baseline in Number of Seizures Recorded on Electroencephalogram (EEG) at the End of the Treatment Period of Core Study and at the End of Extension Phase A
Time frame: Baseline, End of the Treatment Period of Core Study: Week 23, End of Extension Phase A: Week 56
Number of Participants with at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Time frame: From date of first dose of perampanel up to 28 days after the last dose of perampanel (Week 60)
Number of Participants with Treatment Emergent Markedly Abnormal Laboratory Values
Time frame: From date of first dose of perampanel up to Week 60
Number of Participants with Clinically Notable Vital Sign Results
Vital sign measurements include systolic and diastolic blood pressure \[millimeters of Mercury (mmHg)\], pulse (beats per minute), respiratory rate (per minute), temperature (degree centigrade), and weight (kilogram).
Time frame: From date of first dose of perampanel up to 28 days after the last dose of perampanel (Week 60)
Number of Participants with Clinically Significant Abnormal Electrocardiograms
Time frame: From date of first dose of perampanel up to Week 60
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
No publications or documents are linked to this record.
Started May 2019 (actual). Primary completion is estimated for Apr 2027, 94 months after the start.
Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 94 months is above that.
Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perampanel